Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 52Gastrointestinal 42Genitourinary 17Breast 12Sarcoma 10Other solid neoplasm 10Gynecologic 10Tumor-Agnostic 9Head & Neck 8Dermatologic 7CNS 6Lymphoid 4Endocrine 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Carcinoma, Neuroendocrine 2Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mesothelioma, Malignant 1Lung Neoplasms 1Carcinoma, Merkel Cell 1Adenoma, Islet Cell 1Adenocarcinoma, Mucinous 1

Interventions

Magnetic Resonance Spectroscopy 15Specimen Handling 14lutetium Lu 177 dotatate 13Nivolumab 11cabozantinib 10Everolimus 9pembrolizumab 8gallium Ga 68 dotatate 7Ipilimumab 6Cisplatin 6Carboplatin 6Etoposide 5trametinib 4olaparib 4lenvatinib 4X-Rays 4Lutetium-177 4CTLA-4 Antigen 4fluorodopa F 18 3dabrafenib 3cemiplimab 3Surveys and Questionnaires 3Phantoms, Imaging 3Immunoglobulin G 3Fluorodeoxyglucose F18 3Disulfides 3Cyclophosphamide 3Blood Specimen Collection 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
atezolizumab × Endocrine × 90 days × Clear all
NCT05470595 2026-04-15

LCNEC-ALPINE

Technische Universität Dresden

Phase 2 Active not recruiting
67 enrolled
EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡